A Visualized Mortality Prediction Score Model in Hematological Malignancies Patients with Carbapenem-Resistant Organisms Bloodstream Infection

References

• Kois AK, Nicolau DP, Kuti JL. Unresolved issues in the identification and treatment of carbapenem-resistant Gram-negative organisms. Curr Opin Infect Dis. 2020;33(6):482–494. doi:10.1097/qco.0000000000000682
   PubMed Web of Science ®Google Scholar
• McConville TH, Sullivan SB, Gomez-Simmonds A, Whittier S, Uhlemann A-C, Lazzeri C. Carbapenem-resistant Enterobacteriaceae colonization (CRE) and subsequent risk of infection and 90-day mortality in critically ill patients, an observational study. PLoS One. 2017;12(10):e0186195. doi:10.1371/journal.pone.0186195
   PubMed Web of Science ®Google Scholar
• Lee H-J, Choi J-K, Cho S-Y, et al. Carbapenem-resistant Enterobacteriaceae: prevalence and risk factors in a single community-based hospital in Korea. Infect Chemother. 2016;48(3):166–173. doi:10.3947/ic.2016.48.3.166
   PubMed Web of Science ®Google Scholar
• Hovan MR, Narayanan N, Cedarbaum V, Bhowmick T, Kirn TJ. Comparing mortality in patients with carbapenemase-producing carbapenem resistant Enterobacterales and non-carbapenemase-producing carbapenem resistant Enterobacterales bacteremia. Diagn Microbiol Infect Dis. 2021;101(4):115505. doi:10.1016/j.diagmicrobio.2021.115505
   PubMed Web of Science ®Google Scholar
• Blijlevens NM, Donnelly JP, De Pauw BE. Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview. Bone Marrow Transplant. 2000;25(12):1269–1278. doi:10.1038/sj.bmt.1702447
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhang X, Yu W, Lin Z, Chen D. Infection biomarkers in assisting the judgement of blood stream infection and patient prognosis: a retrospective study incorporating principal components analysis. Ann Transl Med. 2020;8(23):1581. doi:10.21037/atm-20-3425
   PubMed Web of Science ®Google Scholar
• Satlin MJ, Jenkins SG, Walsh TJ. The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies. Clin Infect Dis. 2014;58(9):1274–1283. doi:10.1093/cid/ciu052
   PubMed Web of Science ®Google Scholar
• Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer. 2003;98(7):1531–1539. doi:10.1002/cncr.11671
   PubMed Web of Science ®Google Scholar
• Chakrabarti SR, Gupta S, Kumar RS, et al. Gut colonization with carbapenem resistant Enterobacteriaceae adversely impacts the outcome in patients with hematological malignancies: results of a prospective surveillance study. Mediterr J Hematol Infect Dis. 2018;10(1):e2018025. doi:10.4084/mjhid.2018.025
   PubMedGoogle Scholar
• Stewardson AJ, Marimuthu K, Sengupta S, et al. Effect of carbapenem resistance on outcomes of bloodstream infection caused by Enterobacteriaceae in low-income and middle-income countries (PANORAMA): a multinational prospective cohort study. Lancet Infect Dis. 2019;19(6):601–610. doi:10.1016/S1473-3099(18)30792-8
   PubMed Web of Science ®Google Scholar
• Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis. 2014;20(7):1170–1175. doi:10.3201/eid2007.121004
   PubMed Web of Science ®Google Scholar
• Ara-Montojo MF, Escosa-García L, Alguacil-Guillén M, et al. Predictors of mortality and clinical characteristics among carbapenem-resistant or carbapenemase-producing Enterobacteriaceae bloodstream infections in Spanish children. J Antimicrob Chemother. 2021;76(1):220–225. doi:10.1093/jac/dkaa397
   PubMed Web of Science ®Google Scholar
• Trecarichi EM, Pagano L, Martino B, et al. Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey. Am J Hematol. 2016;91(11):1076–1081. doi:10.1002/ajh.24489
   PubMed Web of Science ®Google Scholar
• Lou T, Du X, Zhang P, et al. Risk factors for infection and mortality caused by carbapenem-resistant Klebsiella pneumoniae: a large multicentre case–control and cohort study. J Infect. 2022;84(5):637–647. doi:10.1016/j.jinf.2022.03.010
   PubMed Web of Science ®Google Scholar
• Wu Q, Qian C, Yin H, et al. A novel risk predictive scoring model for predicting subsequent infection after carbapenem-resistant gram-negative bacteria colonization in hematological malignancy patients. Front Oncol. 2022;12:897479. doi:10.3389/fonc.2022.897479
   PubMed Web of Science ®Google Scholar
• (CLSI) CaLSI. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Four Informational Supplement. (CLSI) CaLSI; 2020.
   Google Scholar
• Åkerlund A, Jonasson E, Matuschek E, Serrander L, Sundqvist M, Kahlmeter G. EUCAST rapid antimicrobial susceptibility testing (RAST) in blood cultures: validation in 55 European laboratories. J Antimicrob Chemother. 2020;75(11):3230–3238. doi:10.1093/jac/dkaa333
   PubMed Web of Science ®Google Scholar
• Russell JA. Management of sepsis. N Engl J Med. 2006;355(16):1699–1713. doi:10.1056/NEJMra043632
   PubMed Web of Science ®Google Scholar
• Zhou C, Jin L, Wang Q, et al. Bloodstream infections caused by carbapenem-resistant enterobacterales: risk factors for mortality, antimicrobial therapy and treatment outcomes from a prospective multicenter study. Infect Drug Resist. 2021;14:731–742. doi:10.2147/idr.S294282
   PubMed Web of Science ®Google Scholar
• Satlin MJ, Cohen N, Ma KC, et al. Bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies. J Infect. 2016;73(4):336–345. doi:10.1016/j.jinf.2016.07.002
   PubMed Web of Science ®Google Scholar
• Li C, Li Y, Zhao Z, Liu Q, Li B. Treatment options and clinical outcomes for carbapenem-resistant Enterobacteriaceae bloodstream infection in a Chinese university hospital. J Infect Public Health. 2019;12(1):26–31. doi:10.1016/j.jiph.2018.08.002
   PubMed Web of Science ®Google Scholar
• Vinker-Shuster M, Stepensky P, Temper V, Shayovitz V, Masarwa R, Averbuch D. Gram-negative bacteremia in children with hematologic malignancies and following hematopoietic stem cell transplantation: epidemiology, resistance, and outcome. J Pediatr Hematol Oncol. 2019;41(8):e493–e498. doi:10.1097/mph.0000000000001556
   PubMed Web of Science ®Google Scholar
• Diallo K, Thilly N, Luc A, et al. Management of bloodstream infections by infection specialists: an international ESCMID cross-sectional survey. Int J Antimicrob Agents. 2018;51(5):794–798. doi:10.1016/j.ijantimicag.2017.12.010
   PubMed Web of Science ®Google Scholar
• Rac H, Gould AP, Bookstaver PB, Justo JA, Kohn J, Al-Hasan MN. Evaluation of early clinical failure criteria for gram-negative bloodstream infections. Clin Microbiol Infect. 2020;26(1):73–77. doi:10.1016/j.cmi.2019.05.017
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55(7):943–950. doi:10.1093/cid/cis588
   PubMed Web of Science ®Google Scholar
• Martin A, Fahrbach K, Zhao Q, Lodise T. Association between carbapenem resistance and mortality among adult, hospitalized patients with serious infections due to Enterobacteriaceae: results of a systematic literature review and meta-analysis. Open Forum Infect Dis. 2018;5(7):ofy150. doi:10.1093/ofid/ofy150
   PubMed Web of Science ®Google Scholar
• Reinhart K, Bauer M, Riedemann NC, Hartog CS. New approaches to sepsis: molecular diagnostics and biomarkers. Clin Microbiol Rev. 2012;25(4):609–634. doi:10.1128/cmr.00016-12
   PubMed Web of Science ®Google Scholar
• Póvoa P, Coelho L, Almeida E, et al. Early identification of intensive care unit-acquired infections with daily monitoring of C-reactive protein: a prospective observational study. Crit Care. 2006;10(2):R63. doi:10.1186/cc4892
   PubMed Web of Science ®Google Scholar
• Philip AGS, Mills PC. Use of C-reactive protein in minimizing antibiotic exposure: experience with infants initially admitted to a well-baby nursery. Pediatrics. 2000;106(1):E4. doi:10.1542/peds.106.1.e4
   PubMed Web of Science ®Google Scholar
• Prat C, Sancho JM, Dominguez J, et al. Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia. Leuk Lymphoma. 2008;49(9):1752–1761. doi:10.1080/10428190802258956
   PubMed Web of Science ®Google Scholar
• McMillan DC, Watson WS, O’Gorman P, Preston T, Scott HR, McArdle CS. Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer. 2001;39(2):210–213. doi:10.1207/S15327914nc392_8
   PubMed Web of Science ®Google Scholar
• Fairclough E, Cairns E, Hamilton J, Kelly C. Evaluation of a modified early warning system for acute medical admissions and comparison with C-reactive protein/albumin ratio as a predictor of patient outcome. Clin Med. 2009;9(1):30–33. doi:10.7861/clinmedicine.9-1-30
   PubMed Web of Science ®Google Scholar
• Wang Y, Lin Q, Chen Z, et al. Construction of a risk prediction model for subsequent bloodstream infection in intestinal carriers of carbapenem-resistant Enterobacteriaceae: a retrospective study in hematology department and intensive care unit. Infect Drug Resist. 2021;14:815–824. doi:10.2147/idr.S286401
   PubMed Web of Science ®Google Scholar
• Ishizuka M, Nagata H, Takagi K, Iwasaki Y, Shibuya N, Kubota K. Clinical significance of the C-reactive protein to albumin ratio for survival after surgery for colorectal cancer. Ann Surg Oncol. 2016;23(3):900–907. doi:10.1245/s10434-015-4948-7
   PubMed Web of Science ®Google Scholar
• Zhang W, Liu K, Ye B, Liang W, Ren Y. Pretreatment C-reactive protein/albumin ratio is associated with poor survival in patients with stage IB-IIA cervical cancer. Cancer Med. 2018;7(1):105–113. doi:10.1002/cam4.1270
   PubMed Web of Science ®Google Scholar
• Tang H-N, Pan B-H, Wang L, et al. C-reactive protein-to-albumin ratio is an independent poor prognostic factor in newly diagnosed chronic lymphocytic leukaemia: a clinical analysis of 322 cases. Transl Oncol. 2021;14(4):101035. doi:10.1016/j.tranon.2021.101035
   PubMed Web of Science ®Google Scholar
• Ranzani OT, Zampieri FG, Forte DN, Azevedo LCP, Park M, Salluh JIF. C-reactive protein/albumin ratio predicts 90-day mortality of septic patients. PLoS One. 2013;8(3):e59321. doi:10.1371/journal.pone.0059321
   PubMed Web of Science ®Google Scholar
• Kim MH, Ahn JY, Song JE, et al. The C-reactive protein/albumin ratio as an independent predictor of mortality in patients with severe sepsis or septic shock treated with early goal-directed therapy. PLoS One. 2015;10(7):e0132109. doi:10.1371/journal.pone.0132109
   PubMed Web of Science ®Google Scholar
• Katip W, Uitrakul S, Oberdorfer P. Short-course versus long-course colistin for treatment of carbapenem-resistant A. baumannii in cancer patient. Antibiotics. 2021;10(5):484. doi:10.3390/antibiotics10050484
   Web of Science ®Google Scholar
• Seymour CW, Gesten F, Prescott HC, et al. Time to treatment and mortality during mandated emergency care for sepsis. N Engl J Med. 2017;376(23):2235–2244. doi:10.1056/NEJMoa1703058
   PubMed Web of Science ®Google Scholar
• Bernhard M, Lichtenstern C, Eckmann C, Weigand MA. The early antibiotic therapy in septic patients - milestone or sticking point? Crit Care. 2014;18(6):671. doi:10.1186/s13054-014-0671-1
   PubMed Web of Science ®Google Scholar
• Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34(6):1589–1596. doi:10.1097/01.Ccm.0000217961.75225.E9
   PubMed Web of Science ®Google Scholar
• Ferrer R, Artigas A, Suarez D, et al. Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am J Respir Crit Care Med. 2009;180(9):861–866. doi:10.1164/rccm.200812-1912OC
   PubMed Web of Science ®Google Scholar
• Ferrer R, Martin-Loeches I, Phillips G, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med. 2014;42(8):1749–1755. doi:10.1097/ccm.0000000000000330
   PubMed Web of Science ®Google Scholar
• Falcone M, Bassetti M, Tiseo G, et al. Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae. Crit Care. 2020;24(1):29. doi:10.1186/s13054-020-2742-9
   PubMed Web of Science ®Google Scholar
• Verroken A, Defourny L, Le Polain De Waroux O, et al. Clinical impact of MALDI-TOF MS identification and rapid susceptibility testing on adequate antimicrobial treatment in sepsis with positive blood cultures. PLoS One. 2016;11(5):e0156299. doi:10.1371/journal.pone.0156299
   PubMed Web of Science ®Google Scholar
• Kumar A, Zarychanski R, Light B, et al. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med. 2010;38(9):1773–1785. doi:10.1097/CCM.0b013e3181eb3ccd
   PubMed Web of Science ®Google Scholar
• Vallés J, Rello J, Ochagavía A, Garnacho J, Alcalá MA. Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. Chest. 2003;123(5):1615–1624. doi:10.1378/chest.123.5.1615
   PubMed Web of Science ®Google Scholar
• Seo H, Lee SC, Chung H, et al. Clinical and microbiological analysis of risk factors for mortality in patients with carbapenem-resistant Enterobacteriaceae bacteremia. Int J Antimicrob Agents. 2020;56(4):106126. doi:10.1016/j.ijantimicag.2020.106126
   PubMed Web of Science ®Google Scholar
• Chinese Society of Hematology CM, Chinese Hematology Association, Chinese Medical Doctor Association. 血液肿瘤患者碳青霉烯类耐药的肠杆菌科细菌(CRE)感染的诊治与防控中国专家共识(2020年版) [Management of Carbapenem-resistant Enterobacteriaceae (CRE) infection in patients with hematological malignancies: Chinese consensus (2020)]. Zhonghua Xue Ye Xue Za Zhi. 2020;41(11):881–889. Chinese. doi:10.3760/cma.j.issn.0253-2727.2020.11.001
   PubMedGoogle Scholar
• Livermore DM. Tigecycline: what is it, and where should it be used? J Antimicrob Chemother. 2005;56(4):611–614. doi:10.1093/jac/dki291
   PubMed Web of Science ®Google Scholar
• Doan T-L, Fung HB, Mehta D, Riska PF. Tigecycline: a glycylcycline antimicrobial agent. Clin Ther. 2006;28(8):1079–1106. doi:10.1016/j.clinthera.2006.08.011
   PubMed Web of Science ®Google Scholar
• Yaghoubi S, Zekiy AO, Krutova M, et al. Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review. Eur J Clin Microbiol Infect Dis. 2022;41(7):1003–1022. doi:10.1007/s10096-020-04121-1
   PubMed Web of Science ®Google Scholar
• Stein GE, Babinchak T. Tigecycline: an update. Diagn Microbiol Infect Dis. 2013;75(4):331–336. doi:10.1016/j.diagmicrobio.2012.12.004
   PubMed Web of Science ®Google Scholar
• Vasilev K, Reshedko G, Orasan R, et al. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J Antimicrob Chemother. 2008;62(Suppl Supplement 1):i29–i40. doi:10.1093/jac/dkn249
   PubMedGoogle Scholar
• Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother. 2011;66(9):1963–1971. doi:10.1093/jac/dkr242
   PubMed Web of Science ®Google Scholar
• Cai Y, Wang R, Liang B, Bai N, Liu Y. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother. 2011;55(3):1162–1172. doi:10.1128/aac.01402-10
   PubMed Web of Science ®Google Scholar
• McGovern PC, Wible M, El-Tahtawy A, Biswas P, Meyer RD. All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials. Int J Antimicrob Agents. 2013;41(5):463–467. doi:10.1016/j.ijantimicag.2013.01.020
   PubMed Web of Science ®Google Scholar
• Tasina E, Haidich A-B, Kokkali S, Arvanitidou M. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis. 2011;11(11):834–844. doi:10.1016/S1473-3099(11)70177-3
   PubMed Web of Science ®Google Scholar
• Hung WY, Kogelman L, Volpe G, Iafrati M, Davidson L. Tigecycline-induced acute pancreatitis: case report and literature review. Int J Antimicrob Agents. 2009;34(5):486–489. doi:10.1016/j.ijantimicag.2009.05.004
   PubMed Web of Science ®Google Scholar
• Yahav D, Farbman L, Leibovici L, Paul M. Colistin: new lessons on an old antibiotic. Clin Microbiol Infect. 2012;18(1):18–29. doi:10.1111/j.1469-0691.2011.03734.x
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kasiakou SK, Saravolatz LD. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005;40(9):1333–1341. doi:10.1086/429323
   PubMed Web of Science ®Google Scholar
• Gough M, Hancock RE, Kelly NM. Antiendotoxin activity of cationic peptide antimicrobial agents. Infect Immun. 1996;64(12):4922–4927. doi:10.1128/iai.64.12.4922-4927.1996
   PubMed Web of Science ®Google Scholar
• Avedissian SN, Liu J, Rhodes NJ, et al. A Review of the Clinical Pharmacokinetics of Polymyxin B. Antibiotics. 2019;8(1):31. doi:10.3390/antibiotics8010031
   Web of Science ®Google Scholar
• Liang Q, Huang M, Xu Z. Early use of polymyxin B reduces the mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection. Braz J Infect Dis. 2019;23(1):60–65. doi:10.1016/j.bjid.2018.12.004
   PubMed Web of Science ®Google Scholar
• Cruz DN, Perazella MA, Bellomo R, et al. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care. 2007;11(2):1–12. doi:10.1186/cc5780
   Web of Science ®Google Scholar
• Katip W, Oberdorfer P. Clinical efficacy and nephrotoxicity of colistin alone versus colistin plus vancomycin in critically ill patients infected with carbapenem-resistant Acinetobacter baumannii: a propensity score-matched analysis. Pharmaceutics. 2021;13(2):162. doi:10.3390/pharmaceutics13020162
   PubMed Web of Science ®Google Scholar
• Katip W, Uitrakul S, Oberdorfer P. A Comparison of Colistin versus Colistin Plus Meropenem for the Treatment of Carbapenem-Resistant Acinetobacter baumannii in Critically Ill Patients: a Propensity Score-Matched Analysis. Antibiotics. 2020;9(10):647. doi:10.3390/antibiotics9100647
   Web of Science ®Google Scholar
• Katip W, Oberdorfer P, Kasatpibal N. Effectiveness and nephrotoxicity of loading dose colistin–meropenem versus loading dose Colistin–Imipenem in the treatment of carbapenem-resistant Acinetobacter baumannii infection. Pharmaceutics. 2022;14(6):1266. doi:10.3390/pharmaceutics14061266
   PubMed Web of Science ®Google Scholar
• Katip W, Uitrakul S, Oberdorfer P. Clinical efficacy and nephrotoxicity of the loading dose colistin for the treatment of carbapenem-resistant Acinetobacter baumannii in critically ill patients. Pharmaceutics. 2021;14(1):31. doi:10.3390/pharmaceutics14010031
   PubMed Web of Science ®Google Scholar
• Bush K. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int J Antimicrob Agents. 2015;46(5):483–493. doi:10.1016/j.ijantimicag.2015.08.011
   PubMed Web of Science ®Google Scholar
• van Duin D, Lok JJ, Earley M, et al. Colistin versus Ceftazidime-Avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis. 2018;66(2):163–171. doi:10.1093/cid/cix783
   PubMed Web of Science ®Google Scholar
• Pazzini C, Ahmad-Nejad P, Ghebremedhin B. Ceftolozane/tazobactam susceptibility testing in extended-spectrum betalactamase- and carbapenemase-producing gram-negative bacteria of various clonal lineages. Eur J Microbiol Immunol. 2019;9(1):1–4. doi:10.1556/1886.2019.00001
   Web of Science ®Google Scholar
• Vasques MRG, Bello AR, Da Cruz Lamas C, Correa J, Pereira JAA. β-lactamase producing enterobacteria isolated from surveillance swabs of patients in a cardiac intensive care unit in Rio de Janeiro, Brazil. Braz J Infect Dise. 2011;15(1):28–33.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Ginocchio F, Mikulska M, Taramasso L, Giacobbe DR. Will new antimicrobials overcome resistance among Gram-negatives? Expert Rev Anti Infect Ther. 2011;9(10):909–922. doi:10.1586/eri.11.107
   PubMed Web of Science ®Google Scholar